Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...

CEO Leonard Schleifer highlighted mixed performance ... reflecting higher-than-expected inventory write-offs. Regeneron invested heavily in R&D, advancing its pipeline of 45 clinical candidates.

White & Case secures $405M jury win for Regeneron in antitrust case, with Amgen found liable for anti-competitive bundling ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...

“Regeneron is an American success story ... invented in our New York laboratories,” President and CEO Leonard Schleifer said in a statement. “Our innovative approach has filled our ...

At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Leonard Schleifer; Co-Chairman of the Board, President, Chief Executive Officer, Founder; Regeneron Pharmaceuticals Inc George Yancopoulos; Co-Chairman of the Board, President, Chief Scientific ...